Press Releases

Jasper Therapeutics, Inc., a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024. “Mast cells are

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing. Selected as a preferred supplier, Sartorius will contribute its engineering and manufacturing expertise to commercialize ICB platforms based on prototypes developed by Sanofi. In return, Sanofi will grant Sartorius exclusive access to its know-how and patents related to the ICB platform. Sartorius is committ

Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL‑HF, the first Phase 2 proof-of-concept clinical trial of a phosphodiesterase-9 (PDE9) inhibitor in patients with heart failure. These data were presented today at the Annual Congress of the Heart Failure Association of the European Society of Cardiology taking pla

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, today presented results from new preclinical research demonstrating production of active ALP by a BCM, which highlights BCMs as a potential treatment for Hypophosphatasia (HPP). Researchers used CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design to modify primary human B cells to produce ALP, an enzyme deficient in people living with HPP. The findings we

Fujitsu today announced the development of explainable AI technology that automatically draws on data in multiple formats, including text, images, and numerical data, to create knowledge graphs that will help users to more easily draw meaning from large-scale data sets with high accuracy for areas including medicine. To confirm the effectiveness of this technology, Fujitsu tested it on several key benchmarks from the medical field, including for lung cancer type classification and b

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call.  As the development of genome editing technologies continues to gather pace, Touchlight has developed a novel, circular, single-stranded genome editing template known as MegaBulb DNA (mbDNA™).  Increasing clinical activity with genome edited products is le

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that the Company has been selected for an oral presentation of the abstract titled Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy at the International Society for Cell & Gene Therapy 2024, being held May 28th to June 1st in Van

Alongside its dynamic growth, Vetter announced that it achieved its sustainability goals for 2023. The Contract Development & Manufacturing Organization (CDMO) recently became a member of SBTi and is therefore committed to meeting strict CO2 reduction targets. The pharmaceutical service provider also achieved EcoVadis Platinum status last year, which pushes the company in the top one percent of participants in the globally renowned sustainability ranking. Since 2021, the company has volun

Minaris Regenerative Medicine, a global manufacturing partner to the cell and gene therapy industry, today announced that the first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site. The Allendale facility passed Food and Drug Administration (FDA) pre-Licensing inspections, underscoring the necessary capabilities and expertise to successfully manu

Ligand Pharmaceuticals Incorporated and Agenus Inc., a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with metastatic, relapsed/refractory colorectal cancer not microsatellite insta